Frequency of -163 C>A and 63 C>G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations

被引:16
作者
Dandara, C
Basvi, PT
Bapiro, TE
Sayi, J
Hasler, JA
机构
[1] Univ Zimbabwe, Dept Biochem, Drug Metab Grp, Harare, Zimbabwe
[2] Muhimbili Univ, Coll Hlth Sci, Dept Clin Pharmacol, Dar Es Salaam, Tanzania
关键词
African populations; CYP1A2; polymorphism;
D O I
10.1515/CCLM.2004.152
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Cytochrome P450 1A2 (CYP1A2) is an important member of the cytochrome P450 superfamily of enzymes because of its involvement in the metabolism of some carcinogens and therapeutically important drugs. As a result, factors affecting the activity of the enzyme are the focus of considerable research effort as they may have important pharmacological or toxicological implications. CYP1A2 has been shown to exhibit a genetic polymorphism with most of the data, however, coming from studies in Caucasian and Oriental populations. In this study therefore, we investigated the frequencies of two point mutations, -163C>A and 63C>G, in two Bantu African populations. A total of 214 healthy subjects were recruited from Zimbabwe (n=143) and Tanzania (n=71). The two single nucleotide polymorphisms were detected using polymerase chain reactionrestriction fragment length polymorphism analysis. The frequency of -163A was 57% (95% confidence interval (CI), 54%, 60%) and 49% (95% CI, 45%, 53%) among Zimbabweans and Tanzanians, respectively, but the difference between the two populations was not statistically significant (p=0.123). The base change 63 C>G was not found in any of the subjects from the two populations. We report here a high frequency of -163 C>A base change and an absence of the 63 C>G change in the two African populations.
引用
收藏
页码:939 / 941
页数:3
相关论文
共 19 条
[1]   Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1 [J].
Aklillu, E ;
Carrillo, JA ;
Makonnen, E ;
Hellman, K ;
Pitarque, M ;
Bertilsson, L ;
Ingelman-Sundberg, M .
MOLECULAR PHARMACOLOGY, 2003, 64 (03) :659-669
[2]   A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene:: association with tardive dyskinesia in schizophrenia [J].
Basile, VS ;
Özdemir, V ;
Masellis, M ;
Walker, ML ;
Heltzer, HY ;
Lieberman, JA ;
Potkin, SG ;
Alva, G ;
Kalow, W ;
Macciardi, FM ;
Kennedy, JL .
MOLECULAR PSYCHIATRY, 2000, 5 (04) :410-417
[3]   In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids [J].
Breinholt, VM ;
Offord, EA ;
Brouwer, C ;
Nielsen, SE ;
Brosen, K ;
Friedberg, T .
FOOD AND CHEMICAL TOXICOLOGY, 2002, 40 (05) :609-616
[4]   DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES [J].
BUTLER, MA ;
LANG, NP ;
YOUNG, JF ;
CAPORASO, NE ;
VINEIS, P ;
HAYES, RB ;
TEITEL, CH ;
MASSENGILL, JP ;
LAWSEN, MF ;
KADLUBAR, FF .
PHARMACOGENETICS, 1992, 2 (03) :116-127
[5]   CIGARETTE-SMOKING AND THEOPHYLLINE METABOLISM - EFFECTS OF CIMETIDINE [J].
CUSACK, BJ ;
DAWSON, GW ;
MERCER, GD ;
VESTAL, RE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (03) :330-336
[6]   The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine [J].
Eiermann, B ;
Engel, G ;
Johansson, I ;
Zanger, UM ;
Bertilsson, L .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (05) :439-446
[7]   Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population [J].
Hamdy, SI ;
Hiratsuka, M ;
Narahara, K ;
Endo, N ;
El-Enany, M ;
Moursi, N ;
Ahmed, MSE ;
Mizugaki, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (03) :321-324
[8]   Inducibility of CYP1A2 by orneprazole in vivo related to the genetic polymorphism of CYP1A2 [J].
Han, XM ;
Ouyang, DS ;
Chen, XP ;
Shu, Y ;
Jiang, CH ;
Tan, ZR ;
Zhou, HH .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) :540-543
[9]  
Huang JD, 1999, DRUG METAB DISPOS, V27, P98
[10]   LOW CYP1A2 ACTIVITY IN RURAL SHONA CHILDREN OF ZIMBABWE [J].
MASIMIREMBWA, CM ;
BEKE, M ;
HASLER, JA ;
TANG, BK ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (01) :25-31